Using remote monitoring for cancer patients receiving outpatient chemotherapy
A Pilot Prospective Clinical Trial Using Remote Patient Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
This study is testing whether using wearable devices and an app can help cancer patients receiving outpatient chemotherapy monitor their health and catch any problems early.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Inova Health Care Services Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Fairfax, Virginia) |
| Trial ID | NCT06106360 on ClinicalTrials.gov |
What this trial studies
This pilot study investigates the use of remote monitoring technology to track cancer patients undergoing outpatient chemotherapy. Patients will utilize wearable devices, such as Apple Watches, and an iPhone app developed by Locus Health to continuously monitor vital signs and report symptoms. The study aims to assess the feasibility of this approach by measuring patient engagement and ease of use, as well as the impact on early detection of chemotherapy-related toxicities. By enabling timely medical intervention, the study seeks to improve patient outcomes and reduce healthcare costs.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 or older with solid tumors or hematological malignancies who are starting a new chemotherapy regimen and can comply with the study protocol.
Not a fit: Patients undergoing concurrent radiation therapy may not benefit from this study due to their frequent clinic visits and monitoring.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of complications in cancer patients, improving their overall treatment experience and outcomes.
How similar studies have performed: While remote monitoring in cancer care is an emerging field, this specific approach using wearable devices and mobile applications is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Planned to be treated with a new cytotoxic chemotherapy or chemoimmunotherapy regimen for a solid tumor or malignant hematology condition for at least 4 months * ECOG performance status of 0-2 * Age of 18 or older patient with any solid tumor or hematologic malignancy * English or Spanish speaker * Own an Apple iPhone * Capacity and willingness to provide informed consent Exclusion Criteria: * Patients undergoing concurrent radiation since they will be seen on a daily basis by clinic care teams and are not likely to benefit from active remote patient monitoring * Patients unwilling or unable to comply with the protocol, including wearing the Apple Watch (including recharging daily) and answering queries on the Locus Health iPhone application per the protocol and study group cadence * Any condition for which in the Investigator's opinion would limit compliance with study requirements
Where this trial is running
Fairfax, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia, United States (Recruiting)
Study contacts
- Principal investigator: John Deeken, MD — Inova Schar Cancer Institute
- Study coordinator: Elahe Mollapour
- Email: elahe.mollapour@inova.org
- Phone: (571) 472-4724
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.